Publications by authors named "V Panetta"
Safety and efficacy of bridging intravenous thrombolysis plus mechanical thrombectomy versus direct mechanical thrombectomy in different age groups of acute ischemic stroke patients.
Acta Neurol Belg
October 2024
Objective: To evaluate the safety and efficacy of bridging intravenous thrombolysis plus mechanical thrombectomy (MT) versus direct MT in different age groups of patients with acute ischemic stroke (AIS) secondary to large vessel occlusion (LVO) of the anterior circulation.
Methods: Consecutive patients from the prospective endovascular stroke registry of the Comprehensive Stroke Center, University of Rome Tor Vergata, Italy, between January 2015 and June 2021 were retrospectively analyzed. Patients were divided into age groups (≤ 80 years old and > 80 years old); for each age group, they were further divided in the bridging therapy group and the direct MT group.
Article Synopsis
- Seasonal allergic rhinoconjunctivitis (SAR) is a common problem for many people, especially in Western countries, and researchers studied its connection to different types of pollen and non-pollen allergens.
- The study looked at the IgE antibodies in patients' blood to see how these antibodies reacted to both grass pollen and a specific dust mite allergen.
- The results showed that having more IgE responses to dust mite proteins was linked to having higher overall IgE levels for pollens, but lower levels for the dust mite allergen itself.
Background: In Europe, Omalizumab (anti-IgE) is indicated for the treatment of moderate to severe asthma, but not for IgE-mediated food allergy (FA).
Objective: We assessed the impact of Omalizumab on efficacy, safety, and quality of life (FA-QoL) in patients with moderate to severe asthma and who have a history of anaphylaxis to peanut, tree nuts, fish, egg, milk, and/or wheat.
Methods: Food-allergic children (6-18 years) with moderate to severe asthma underwent oral food challenges (OFCs) to establish the threshold of reaction to the culprit food(s) at baseline (T0) and at 4-month intervals (T1, T2, and T3) during their first year of treatment with Omalizumab.
Article Synopsis
- Metabolic syndrome (MS) is linked to hepatocellular carcinoma (HCC), prompting a study on the long-term outcomes of liver resections in MS patients.
- Data from 813 patients over 20 years showed a median overall survival of 81.4 months, with a recurrence rate of 48.3%, often peaking at 6 and 24 months post-surgery.
- The study concluded that while patients have favorable long-term outcomes, the timing and nature of recurrences—linked to tumor features and cirrhosis—play a crucial role in survival, highlighting the need for careful post-operative monitoring.
Objectives: Cladribine tablets (CLAD) for adult patients with highly active relapsing multiple sclerosis (RMS) have been available in Italy since 2018. We aimed to assess predictors of no-evidence-of-disease-activity-3 (NEDA-3) status after 24 months of the last dose of CLAD.
Results: We included 88 patients (70.